Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes.
Fiche du document
5 septembre 2023
- doi: 10.1073/pnas.2302720120
- issn: 0027-8424
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1073/pnas.2302720120
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37643212
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1091-6490
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_017FA8B8CC9B6
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Diseases and hygiene Group dynamics Association Groups, Social Sickness Human beings--Diseases Morbidity Illness Sicknesses IllnessesCiter ce document
Y. Le Guen et al., « Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes. », Serveur académique Lausannois, ID : 10.1073/pnas.2302720120
Métriques
Partage / Export
Résumé
Across multiancestry groups, we analyzed Human Leukocyte Antigen (HLA) associations in over 176,000 individuals with Parkinson's disease (PD) and Alzheimer's disease (AD) versus controls. We demonstrate that the two diseases share the same protective association at the HLA locus. HLA-specific fine-mapping showed that hierarchical protective effects of HLA-DRB1*04 subtypes best accounted for the association, strongest with HLA-DRB1*04:04 and HLA-DRB1*04:07, and intermediary with HLA-DRB1*04:01 and HLA-DRB1*04:03. The same signal was associated with decreased neurofibrillary tangles in postmortem brains and was associated with reduced tau levels in cerebrospinal fluid and to a lower extent with increased Aβ42. Protective HLA-DRB1*04 subtypes strongly bound the aggregation-prone tau PHF6 sequence, however only when acetylated at a lysine (K311), a common posttranslational modification central to tau aggregation. An HLA-DRB1*04-mediated adaptive immune response decreases PD and AD risks, potentially by acting against tau, offering the possibility of therapeutic avenues.
